Possible Role of 5-Alpha Reductase Inhibitors in Non-Invasive Bladder Urothelial Neoplasm: Multicentre Study
December 2019
in “
Minerva Urology and Nephrology
”
TLDR 5-alpha reductase inhibitors may reduce bladder cancer recurrence and improve survival.
The study evaluated the role of 5-alpha reductase inhibitors (5-ARIs) in non-muscle invasive bladder cancer (NMIBC) by retrospectively analyzing data from 423 patients. Patients treated with 5-ARIs had a significantly lower recurrence rate (14%) compared to untreated patients (37%), and a higher recurrence-free survival rate. The treated group also had fewer high-grade tumors and muscle invasive tumors. The findings suggested that long-term 5-ARI treatment might reduce bladder tumor recurrence and lesion extension, and improve recurrence-free survival. The study recommended a long-term, randomized prospective study to confirm these results.